Theranostics 2020; 10(23):10589-10605. doi:10.7150/thno.47176 This issue Cite

Research Paper

EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy

Shuli Liu1,2,3,*, Yang Wang1,2,3,*, Yong Han1,3,*, Weiya Xia4, Ling Zhang1,3, Shengming Xu1,3, Houyu Ju1,3, Xiangkai Zhang1,3, Guoxin Ren1,3, Liu Liu1,3, Weimin Ye1,3✉, Zhiyuan Zhang1,3✉, Jingzhou Hu1,3✉

1. Department of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
2. Laboratory of Oral Microbiota and Systemic Diseases, Shanghai Ninth People's Hospital, College of Stomatology, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
3. National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, Shanghai, China.
4. Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
*Shuli Liu, Yang Wang and Yong Han equally contributed to this work

Citation:
Liu S, Wang Y, Han Y, Xia W, Zhang L, Xu S, Ju H, Zhang X, Ren G, Liu L, Ye W, Zhang Z, Hu J. EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy. Theranostics 2020; 10(23):10589-10605. doi:10.7150/thno.47176. https://www.thno.org/v10p10589.htm
Other styles

File import instruction

Abstract

Graphic abstract

Rationale: The oncogenesis of head and neck squamous cell carcinoma (HNSCC) is believed to result from oncogene activation and tumor suppressor inactivation. Here, we identified a new oncogenic role for the EREG gene in HNSCC.

Methods: The TCGA database and immunohistochemistry assay were used to analyze expression of EREG in HNSCC tissues. Immunoblotting was performed to identify the EGFR-mediated pathways altered by EREG. The role of EREG in oncogenesis was investigated in vivo and in vitro.

Results: Upregulated EREG expression predicted a poor prognosis and triggered HNSCC oncogenic transformation by activating the epidermal growth factor receptor (EGFR) signaling pathway. We also demonstrated the direct association of EREG with EGFR and that this binding required EGFR domains I and III and the N57 residue of EREG. Moreover, EREG overexpression was shown to promote HNSCC oncogenesis by inducing C-Myc expression, and the pharmacological inhibition of C-Myc rescued EREG-promoted HNSCC oncogenesis. Unlike other EGFR ligands, EREG could mimic EGFR mutations by sustaining the activation of the EGFR-Erk pathway, and high EREG expression was positively associated with the response to treatment with the EGFR inhibitor erlotinib. Furthermore, knockdown of EREG decreased sensitivity to erlotinib treatment in vitro and in vivo.

Conclusions: These results identify the EREG-EGFR-C-Myc pathway as a crucial axis that drives HNSCC oncogenesis and show that EREG expression could be a predictive functional marker of sensitivity to erlotinib therapy in HNSCC.

Keywords: Epiregulin, HNSCC, EGFR, C-Myc, Erlotinib


Citation styles

APA
Liu, S., Wang, Y., Han, Y., Xia, W., Zhang, L., Xu, S., Ju, H., Zhang, X., Ren, G., Liu, L., Ye, W., Zhang, Z., Hu, J. (2020). EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy. Theranostics, 10(23), 10589-10605. https://doi.org/10.7150/thno.47176.

ACS
Liu, S.; Wang, Y.; Han, Y.; Xia, W.; Zhang, L.; Xu, S.; Ju, H.; Zhang, X.; Ren, G.; Liu, L.; Ye, W.; Zhang, Z.; Hu, J. EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy. Theranostics 2020, 10 (23), 10589-10605. DOI: 10.7150/thno.47176.

NLM
Liu S, Wang Y, Han Y, Xia W, Zhang L, Xu S, Ju H, Zhang X, Ren G, Liu L, Ye W, Zhang Z, Hu J. EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy. Theranostics 2020; 10(23):10589-10605. doi:10.7150/thno.47176. https://www.thno.org/v10p10589.htm

CSE
Liu S, Wang Y, Han Y, Xia W, Zhang L, Xu S, Ju H, Zhang X, Ren G, Liu L, Ye W, Zhang Z, Hu J. 2020. EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy. Theranostics. 10(23):10589-10605.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image